Delayed trial readouts

Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.

Summary

2,453 date moves: 1,669 later and 784 earlier. The median move later is 246 days.

Date moves

SeenDrugStudyPhaseOld dateNew dateMove
2026-11-20aldesleukinNCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Phase 32021-09-302025-01-30+1218 days
2026-11-20Gemcitabine, SintilimabNCT05979818Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerPhase 1/22025-08-312028-10-31+1157 days
2026-11-20NMS-03597812NCT06549790Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 12029-09-152026-09-24−1087 days
2026-11-20Capecitabine, Gemcitabine, Eribulin mesylateNCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerPhase 32025-122027-12-31+760 days
2026-11-20Dexamethasone, Ofatumumab, Rituximab, Blinatumomab, MethotrexateNCT02877303Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaPhase 22026-11-012028-11-01+731 days
2026-11-20MethotrexateNCT06252870Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft TransplantationPhase 22027-10-182029-10-18+731 days
2026-11-20Bortezomib, AbataceptNCT05289167Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)Phase 1/22026-082027-11+457 days
2026-11-20Disitamab VedotinNCT06660511Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.Phase 12025-09-012026-12-01+456 days
2026-11-20Semaglutide (Ozempic)NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous SemaglutidePhase 2/32027-012027-12+334 days
2026-11-20PembrolizumabNCT06249048Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabPhase 1/22027-052026-06-17−318 days
2026-11-20EsomeprazoleNCT06561542A Phase I Study of LX22001 for Injection in Healthy SubjectsPhase 12025-11-212025-01-23−302 days
2026-11-20AtezolizumabNCT05498896Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCPhase 22026-08-312027-05-31+273 days
2026-11-20Elacestrant, AbemaciclibNCT05386108Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerPhase 1/22026-122027-08+243 days
2026-11-20LetrozoleNCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)Phase 32027-07-012028-02-01+215 days
2026-11-20Ferric derisomaltoseNCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in PregnancyPhase 32026-12-312026-05-31−214 days
2026-11-20BlinatumomabNCT03595917ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLPhase 12026-11-012027-06-01+212 days
2026-11-20Capivasertib, OsimertinibNCT07486648Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibPhase 1/22028-10-152029-05-15+212 days
2026-11-20SelinexorNCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Phase 22026-122026-06-02−182 days
2026-11-20SapanisertibNCT06385496Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Phase 22026-12-312027-06-30+181 days
2026-11-20SapanisertibNCT06390865Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Phase 22026-12-312027-06-30+181 days
2026-11-20Axitinib intravitreal implant (OTX-TKI)NCT05695417Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic RetinopathyPhase 12024-012024-05-28+148 days
2026-11-20BI 3000202NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodPhase 12027-02-212026-10-11−133 days
2026-11-20ontunisertibNCT07672574Human Mass Balance Study of [14C] Ontunisertib in Healthy VolunteersPhase 12026-09-262027-01-31+127 days
2026-11-20Rifaximin SSDNCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPhase 32025-092025-12-23+113 days
2026-11-20ExemestaneNCT03125746A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsPhase 12021-10-282021-07-21−99 days
2026-11-20Zoledronic acidNCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of BonePhase 32027-012027-04+90 days
2026-11-20Oxycodone (Xtampza ER)NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing.Phase 32026-12-312027-03-31+90 days
2026-11-20Xanomeline/trospium chlorideNCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsPhase 12026-12-032026-09-28−66 days
2026-11-20GoserelinNCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)Phase 32035-102035-12+61 days
2026-11-20SHR-1139NCT07078695A Trial of SHR-1139 in Healthy VolunteersPhase 12026-09-302026-11-09+40 days
2026-11-20Semaglutide (Wegovy)NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsPhase 32031-022031-03+28 days
2026-11-20PembrolizumabNCT03161431SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabPhase 12026-082026-07-31−1 day
2026-11-20AR1001NCT03625622Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseasePhase 22020-12-222020-12-21−1 day
2026-11-19NivolumabNCT05795244Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)Phase 22029-122026-02-24−1376 days
2026-11-19AnakinraNCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenPhase 32025-06-012027-10-01+852 days
2026-11-19SilevertinibNCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsPhase 1/22025-11-032028-03+849 days
2026-11-19Trastuzumab Deruxtecan, AfatinibNCT06085755Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerPhase 1/22025-122027-12-01+730 days
2026-11-19PregabalinNCT04322305Pregabalin Trial for the Treatment of Alcohol Use DisorderPhase 22025-06-302023-07-31−700 days
2026-11-19CRMA-1001NCT07200193A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis BPhase 1/22032-12-312031-02−699 days
2026-11-19ColesevelamNCT06197763Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.Phase 1/22025-11-012027-07-30+636 days
2026-11-19FulvestrantNCT05826964Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerPhase 22026-07-312027-11-30+487 days
2026-11-19Niraparib, BevacizumabNCT04734665Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorPhase 22023-03-312024-07-11+468 days
2026-11-19AlmonertinibNCT06463171Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerPhase 22026-062027-08-01+426 days
2026-11-19tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), BictegravirNCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedPhase 2/32028-012026-11-03−424 days
2026-11-19Dexamethasone, DocetaxelNCT04947189Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast CancerPhase 1/22026-072027-07-01+365 days
2026-11-19Azacitidine, VenetoclaxNCT07163793Pilot Study of Reduced Venetoclax ExposurePhase 22026-102027-10+365 days
2026-11-19Ruxolitinib (Jakafi), AbataceptNCT07238712Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorPhase 22026-12-102027-12-10+365 days
2026-11-19TislelizumabNCT07389187Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 12026-122027-12+365 days
2026-11-19SelpercatinibNCT05668962Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCPhase 22025-03-012026-01-13+318 days
2026-11-19teduglutide (Gattex)NCT07400783TED_ORG: Study on Short Bowel SyndromePhase na2026-032027-01+306 days
2026-11-19Tamoxifen (Soltamox)NCT05156892Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian CancerPhase 12026-01-012026-11-01+304 days
2026-11-19CadonilimabNCT05063916Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the CervixPhase 22027-08-012026-11-11−263 days
2026-11-19Methylprednisolone, abrocitinib, tofacitinibNCT06119490Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisPhase 12026-072025-10-14−260 days
2026-11-19Sacituzumab GovitecanNCT04559230Sacituzumab Govitecan in Recurrent GlioblastomaPhase 22027-022027-08+181 days
2026-11-19PovetaciceptNCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Phase 2/32028-12-292029-06-27+180 days
2026-11-19PF-08634404, PembrolizumabNCT06980272SSGJ-707 in Advanced Non-Small Cell Lung CancerPhase 32026-07-302026-02-01−179 days
2026-11-19Psilocybin (COMP360)NCT07373535Understanding Music and Mindfulness Preferences in Psilocybin-Assisted PsychotherapyPhase 22028-072028-12+153 days
2026-11-19TicagrelorNCT06691191Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 InhibitorsPhase 42026-08-312026-12-31+122 days
2026-11-19AND017NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPhase 32026-10-302027-02-20+113 days
2026-11-19Tremelimumab, Olaparib, DurvalumabNCT03699449An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Phase 22022-092022-05-17−107 days
2026-11-19AND017NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Phase 32026-12-012027-03-01+90 days
2026-11-19NivolumabNCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaPhase 12027-01-312026-11-12−80 days
2026-11-19tocilizumabNCT05207670A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesPhase 22027-07-312027-10-01+62 days
2026-11-19efsubaglutide alfaNCT07114419The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)Phase 22026-06-012026-07-06+35 days
2026-11-19Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, CarfilzomibNCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPhase 32028-10-312028-11-30+30 days
2026-11-19tilrekimigNCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of TimePhase 32034-05-122034-04-21−21 days
2026-11-19Depemokimab, MepolizumabNCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Phase 32026-09-292026-10-06+7 days
2026-11-19stapokibartNCT05728684Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related DiseasePhase na2024-02-282024-02-26−2 days
2026-11-18Sintilimab, BevacizumabNCT05363722Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCCPhase 12023-042029-01+2102 days
2026-11-18Patritumab DeruxtecanNCT06172478A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 22027-09-012030-11-19+1175 days
2026-11-18MitapivatNCT05935202Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesPhase 22025-07-152028-09-30+1173 days
2026-11-18ObudanersenNCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromePhase 1/22029-032032-03+1096 days
2026-11-18Tretinoin, PembrolizumabNCT06484920A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLPhase 22027-122025-06-03−911 days
2026-11-18Tobevibart (VIR-3434)NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPhase 22026-112029-03+851 days
2026-11-18Futibatinib (Lytgobi), Amivantamab, AtezolizumabNCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)Phase 22025-052027-05+730 days
2026-11-18IvabradineNCT04111133Ivabradine in Cirrhotic CardiomyopathyPhase na2024-102026-10-01+730 days
2026-11-18Gemcitabine, S-1, TislelizumabNCT06903273Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk CholangiocarcinomaPhase 22028-07-012030-07-01+730 days
2026-11-18tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, BictegravirNCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityPhase 32026-06-052027-12-05+548 days
2026-11-18LetrozoleNCT06913075FET in AdenomyosisPhase na2026-07-152027-09-15+427 days
2026-11-18Ipilimumab, Nivolumab, tocilizumabNCT04940299Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaPhase 22027-12-312026-11-11−415 days
2026-11-18INCB123667NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 32028-11-152027-10-12−400 days
2026-11-18TemozolomideNCT04910022Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaPhase 1/22027-05-302026-05-06−389 days
2026-11-18Dexamethasone, IxazomibNCT03618537Ixazomib Maintenance Study in Patients With AL AmyloidosisPhase 22026-082027-08+365 days
2026-11-18BinimetinibNCT06159478Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic CancerPhase 22027-02-282028-02-28+365 days
2026-11-18Rifaximin (Xifaxan)NCT06538077BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HEPhase 42026-082027-08+365 days
2026-11-18Cannabidiol (Epidiolex)NCT06014424Cannabidiol Medication Intervention TrialPhase 22026-12-292027-12+337 days
2026-11-18Gemcitabine, AtezolizumabNCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerPhase 32027-06-012026-07-23−313 days
2026-11-18IAM1363NCT06253871A Phase 1/2 Study of IAM1363 in HER2 CancersPhase 1/22027-122028-10+305 days
2026-11-18Diroximel fumarateNCT06913920Mechanical Modalities Combined With Standard Therapy Versus Standard Therapy Alone for Edema and Pain Management After Distal Radius Fracture FixationPhase na2026-01-152026-10-28+286 days
2026-11-18Pembrolizumab, BlinatumomabNCT03512405Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaPhase 1/22025-11-112025-01-31−284 days
2026-11-18Methotrexate, etanerceptNCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiSPhase 32025-02-282025-10-31+245 days
2026-11-18EntrectinibNCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Phase 22027-06-302026-10-29−244 days
2026-11-18Diroximel fumarateNCT06913894Supervised vs. Home-Based vs. No Therapy for Uncomplicated Distal Radius Fracture in Younger AdultsPhase na2026-04-212026-10-27+189 days
2026-11-18faricimabNCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRPhase 32031-082032-02+184 days
2026-11-18Insulin LisproNCT06945406A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesPhase 12027-032027-07+122 days
2026-11-18viloxazineNCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Phase 32026-092026-12+91 days
2026-11-18Ranibizumab, Surabgene lomparvovecNCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Phase 22026-082026-10-13+73 days
2026-11-18TemozolomideNCT06931626Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerPhase 12026-10-302026-08-20−71 days
2026-11-18ARV-806NCT07023731A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationPhase 1/22026-11-302026-10-30−31 days
2026-11-18DepemokimabNCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPhase 32029-04-302029-04-02−28 days
2026-11-18TemozolomideNCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPhase 32035-11-022035-11-30+28 days
2026-11-18InclisiranNCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesPhase 32027-02-112027-01-16−26 days
2026-11-18TafolecimabNCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaPhase 32026-09-062026-08-26−11 days
2026-11-18FelcorekibartNCT07915791A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Phase 22029-03-162029-03-07−9 days
2026-11-18RabeprazoleNCT07797478A Study of RO7890597 in Healthy Adult VolunteersPhase 12027-06-082027-06-15+7 days
2026-11-17Duloxetine, Pregabalin, GabapentinNCT07593313Treatment of Post-Stroke Central PainPhase na2026-08-012029-08-01+1096 days
2026-11-17AvelumabNCT03774901Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile CarcinomaPhase 22024-09-222026-10-30+768 days
2026-11-17zanubrutinib, RituximabNCT05914662Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMPhase 22025-03-152026-11-15+610 days
2026-11-17zasocitinibNCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPhase 32033-01-242034-07-03+525 days
2026-11-17Bevacizumab, Nab-paclitaxel, Relacorilant (Lifyorli)NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersPhase 22026-082027-12+487 days
2026-11-17RamucirumabNCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyPhase 22027-092026-07-09−419 days
2026-11-17TSN1611NCT06385925A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D MutationPhase 1/22026-10-302027-10-30+365 days
2026-11-17PembrolizumabNCT03829254A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and LymphomaPhase 1/22026-082027-07+334 days
2026-11-17EmpagliflozinNCT07472920Empagliflozin Adjunctive Therapy in Bipolar DepressionPhase na2026-092027-08+334 days
2026-11-17dupilumabNCT05268107Ethnic Differences in Mechanisms of Action of DupilumabPhase 42026-122027-07+212 days
2026-11-17RituximabNCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaPhase 22026-10-012027-05-01+212 days
2026-11-17Corteria COR-1167NCT06815471CRF2 Agonist for the Treatment of Worsening Heart FailurePhase 22026-122027-07+212 days
2026-11-17Nab-paclitaxel, GemcitabineNCT05064618Investigator-initiated Clinical Trial of MIKE-1Phase 1/22025-04-302025-10-02+155 days
2026-11-17Axatilimab, PembrolizumabNCT07015853ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationPhase 22033-072033-12+153 days
2026-11-17DurvalumabNCT03768570Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder CancerPhase 22026-10-312027-03-31+151 days
2026-11-17Iparomlimab and tuvonralimabNCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerPhase 32032-08-312032-12-31+122 days
2026-11-17Dostarlimab, NiraparibNCT04068753Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerPhase 22026-122026-08-06−117 days
2026-11-17HRG2010NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor FluctuationsPhase 32025-10-092026-01-29+112 days
2026-11-17PembrolizumabNCT07732634Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerPhase 22029-082029-11+92 days
2026-11-17DostarlimabNCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerPhase 32029-12-122030-03-13+91 days
2026-11-17Daraxonrasib, Nab-paclitaxel, GemcitabineNCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 32028-062028-04−61 days
2026-11-17GFH276NCT07198321A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsPhase 1/22027-09-222027-07-30−54 days
2026-11-17Purinostat MesylateNCT07809217Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy ParticipantsPhase 12026-10-312026-12-15+45 days
2026-11-17VT-5006NCT07310264Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's DiseasePhase 12026-09-282026-11-10+43 days
2026-11-17AxatilimabNCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Phase 22026-092026-08-27−5 days
2026-11-14Ceralasertib, DurvalumabNCT03780608A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L)Phase 22022-12-012027-12-01+1826 days
2026-11-14BI 3000202NCT06878365A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 InterferonopathiesPhase 12026-12-062029-12-10+1100 days
2026-11-14Oxycodone (Xtampza ER)NCT04659317Opioid-Free OrthopaedicsPhase 32028-122026-07-20−865 days
2026-11-14Elranatamab, Lenalidomide, DaratumumabNCT06931704Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Phase 22030-11-302028-11-30−730 days
2026-11-14Rosuvastatin, LaroprovstatNCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPhase 2/32025-07-032027-02-22+599 days
2026-11-14NabiximolsNCT05503147Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)Phase 12023-08-012025-01-15+533 days
2026-11-14OrcaGraft (Orca-Q)NCT06900192A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple SclerosisPhase 12029-082028-06−426 days
2026-11-14OsimertinibNCT05748093Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatPhase 42026-06-012027-07-01+395 days
2026-11-14Omega-3-acid ethyl esters (Lovaza)NCT02178410VITAL Rhythm StudyPhase 32026-102027-10+365 days
2026-11-14pemetrexed, Adebrelimab, Nab-paclitaxelNCT05794477A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid TumorsPhase 1/22025-07-012024-08-20−315 days
2026-11-14obefazimodNCT07453784Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet FormulationPhase 12026-092027-04+212 days
2026-11-14aldesleukinNCT06107894TIL Therapy for Patients With Advanced Solid TumorsPhase 12025-092026-02-28+180 days
2026-11-14metforminNCT04931017Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung CancerPhase 22026-12-312026-07-09−175 days
2026-11-14VosoritideNCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentPhase 22027-032026-09-16−166 days
2026-11-14upadacitinibNCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyPhase 32028-032028-08+153 days
2026-11-14Gemcitabine, DurvalumabNCT07332351Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialPhase 22027-01-012027-06-01+151 days
2026-11-14Trastuzumab Emtansine, InavolisibNCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 32026-12-312027-05-03+123 days
2026-11-14BGM0504NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePhase 32026-11-142026-08-13−93 days
2026-11-14ADSTEMNCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPhase 32029-062029-09+92 days
2026-11-14SuzetrigineNCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic SurgeryPhase 32026-12-312027-03-31+90 days
2026-11-14AZD4954NCT07812077A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954Phase 12026-12-172027-03-17+90 days
2026-11-14BGM0504, Semaglutide (Ozempic)NCT06716216A Study of BGM0504 in Participants With Type 2 DiabetesPhase 32026-11-142026-08-25−81 days
2026-11-14survodutideNCT07407348A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyPhase 12027-01-262027-04-09+73 days
2026-11-14maralixibatNCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Phase 32026-102026-07-29−64 days
2026-11-14OmalizumabNCT06618963Effect of Omalizumab in the Skin of Food Allergy PatientsPhase 42026-092026-11-03+63 days
2026-11-14Bempedoic acidNCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic AcidPhase 32025-102025-08-05−57 days
2026-11-14BenralizumabNCT04565483Predictive Signature of Benralizumab ResponsePhase 42026-102026-08-19−43 days
2026-11-14EsketamineNCT05212571Long-term Pain Modulation by Intravenous Esketamine in CRPSPhase na2026-10-012026-08-20−42 days
2026-11-14setmelanotideNCT06772597A Study of Setmelanotide in Patients With Prader-Willi SyndromePhase 22026-10-312026-11-03+3 days
2026-11-14BenralizumabNCT03953300Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsPhase 42026-10-192026-10-20+1 day
2026-11-13NivolumabNCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsPhase 22022-12-152030-12-15+2922 days
2026-11-13IbrutinibNCT02787369ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLPhase 12026-042019-06−2496 days
2026-11-13AxitinibNCT06485908Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and EpendymomaPhase 1/22026-042032-02+2132 days
2026-11-13tenofovir alafenamide (Vemlidy)NCT04939441Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)Phase 42024-05-012027-12-31+1339 days
2026-11-13SerplulimabNCT05311189Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric CancerPhase 22023-12-312026-12-31+1096 days
2026-11-13MavacamtenNCT07807384Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyPhase 42026-092029-09+1096 days
2026-11-13LBL-034NCT06049290A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaPhase 1/22026-10-202029-09-20+1066 days
2026-11-13MethylprednisoloneNCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical TrialPhase 32027-01-312029-01-31+731 days
2026-11-13AtezolizumabNCT05681039Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Phase 22026-11-012028-11-01+731 days
2026-11-13Sargramostim, Ipilimumab, PembrolizumabNCT04739618Metastatic Solid Cancer Clinical TrialPhase 22024-122026-11-10+709 days
2026-11-13IRX4204NCT06723171Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque PsoriasisPhase 22026-032027-12+640 days
2026-11-13RituximabNCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Phase 22026-09-302028-05-31+609 days
2026-11-13AK146D1NCT06929663A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid TumorsPhase 12026-11-052028-06-30+603 days
2026-11-13pemetrexed, CadonilimabNCT06762080Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal MetastasisPhase 1/22026-10-302027-12-30+426 days
2026-11-13infliximabNCT06758024PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel DiseasePhase na2026-012027-03+424 days
2026-11-13AnakinraNCT03587701Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear DiseasePhase 22026-12-312027-12-31+365 days
2026-11-13EpcoritamabNCT06510361A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront TherapyPhase 22026-05-012027-05-01+365 days
2026-11-13Decitabine/cedazuridine (Inqovi)NCT05178693Lutathera and ASTX727 in Neuroendocrine TumoursPhase 12026-06-302027-05-30+334 days
2026-11-13CetuximabNCT06447987Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic LeukemiaPhase 12026-12-052027-10-29+328 days
2026-11-13Ifebemtinib, FurmonertinibNCT05994131IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCPhase 1/22026-07-312025-09-20−314 days
2026-11-13LAE102NCT06493084Evaluate LAE102 in Healthy and Overweight/Obese SubjectsPhase 12026-09-302027-06-30+273 days
2026-11-13SotorasibNCT06659341A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C MutationPhase 12027-04-262027-11-30+218 days
2026-11-13TislelizumabNCT06420440Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelPhase 22026-05-312026-12-31+214 days
2026-11-13Naloxone (Narcan)NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into TreatmentPhase 32026-08-312026-01-30−213 days
2026-11-13NiraparibNCT05694715Combination Therapy in Cancers With Mutations in DNA Repair GenesPhase 12028-01-312028-08-31+213 days
2026-11-13Lithium salicylate/L-proline (AL001)NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderPhase 1/22026-122027-07+212 days
2026-11-13RituximabNCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Phase 1/22027-05-312026-11-06−206 days
2026-11-13Pelcitoclax, OsimertinibNCT04001777A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsPhase 12025-122025-05-27−188 days
2026-11-13Diroximel fumarateNCT06913933Static vs. Dynamic Progressive Splinting for Persistent Wrist Stiffness After DRFPhase na2026-04-172026-10-08+174 days
2026-11-13Dexamethasone, Lenalidomide, Daratumumab, CarfilzomibNCT03606577An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsPhase 22022-02-082022-07-18+160 days
2026-11-13XTR003NCT07443696PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic CardiomyopathyPhase 22026-082026-12-31+152 days
2026-11-13Emtricitabine (Emtriva), tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Dolutegravir, VH4524184NCT07202546A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)Phase 22027-06-112027-10-28+139 days
2026-11-13Docetaxel, OSE2101NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPhase 32027-12-152028-05-01+138 days
2026-11-13BI 3000202NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodPhase 12026-10-062027-02-21+138 days
2026-11-13EsketamineNCT07753772Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral ReconstructionPhase 42029-072029-11+123 days
2026-11-13BI 3000202NCT07486102A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver ProblemsPhase 12027-02-262026-10-30−119 days
2026-11-13SuzetrigineNCT07538570Evaluation of Pain Treatment After Total Knee ArthroplastyPhase 42027-01-302026-10-12−110 days
2026-11-13VosoritideNCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPhase 32026-08-012026-04-23−100 days
2026-11-13tocilizumab, Iberdomide, ObinutuzumabNCT05169515A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaPhase 12029-08-052029-04-30−97 days
2026-11-13BofanglutideNCT07144098Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionPhase 12026-07-122026-04-07−96 days
2026-11-13IfebemtinibNCT06014528IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerPhase 22026-12-242027-03-24+90 days
2026-11-13SaruparibNCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesPhase 12026-10-022026-12-31+90 days
2026-11-13Erfonrilimab, Ifebemtinib, Nab-paclitaxel, GemcitabineNCT05827796IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerPhase 1/22025-12-312025-10-11−81 days
2026-11-13tulisokibartNCT07133633A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Phase 22027-06-152027-03-29−78 days
2026-11-13VadadustatNCT06520826Vafseo Outcomes In-Center ExperiencePhase 32026-06-302026-09-10+72 days
2026-11-13Semaglutide (Wegovy), survodutideNCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityPhase 12027-01-082026-11-01−68 days
2026-11-13AcoramidisNCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisPhase 42027-07-152027-09-17+64 days
2026-11-13Naloxone (Narcan)NCT05027919Assessing a Clinically-meaningful Opioid Withdrawal PhenotypePhase 22026-11-302027-01-30+61 days
2026-11-13EsketamineNCT07625826The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid SurgeryPhase na2027-052027-03−61 days
2026-11-13GabapentinNCT06565546CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia RepairsPhase na2026-09-012026-10-31+60 days
2026-11-13EverolimusNCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 32026-12-302027-02-26+58 days
2026-11-13barzolvolimabNCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Phase 32026-102026-08-04−58 days
2026-11-13tenofovir alafenamide (Vemlidy), Tenofovir disoproxil fumarate (Viread)NCT02932150Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionPhase 22026-092026-10-27+56 days
2026-11-13barzolvolimabNCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPhase 32026-102026-08-12−50 days
2026-11-13MET-233iNCT07022977A Study of MET233 in Individuals With Obesity or OverweightPhase 12026-04-212026-05-28+37 days
2026-11-13BofanglutideNCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsPhase 32026-052026-03-26−36 days
2026-11-13MT-201NCT07219368A First-in-Human Single and Multiple Ascending Dose Study of MT-201Phase 12026-11-242026-10-20−35 days
2026-11-13Ifebemtinib, TislelizumabNCT06030258IN10018 Combination Therapy in Treatment-naïve ES-SCLCPhase 1/22025-12-242025-11-20−34 days
2026-11-13tocilizumab, PembrolizumabNCT07889232Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung CancerPhase 1/22029-04-302029-05-31+31 days
2026-11-13GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32029-01-012029-01-31+30 days
2026-11-13Odronextamab, RituximabNCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPhase 32028-02-072028-02-29+22 days
2026-11-13GSK4527363NCT06576271A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsPhase 12028-01-112028-02-01+21 days
2026-11-13IfebemtinibNCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian CancerPhase 1/22026-05-312026-05-11−20 days
2026-11-13Ruxolitinib (Opzelura)NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Phase 32026-10-092026-10-29+20 days
2026-11-13AlimatravirNCT07661108A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)Phase 12026-10-092026-10-28+19 days
2026-11-13precemtabart tocentecanNCT06806046Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsPhase 12026-09-302026-09-23−7 days
2026-11-13Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, CarfilzomibNCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 32026-08-302026-08-26−4 days
2026-11-13setmelanotideNCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPhase 32025-12-222025-12-19−3 days
2026-11-13Pegcetacoplan, BI 771716NCT06722157A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPhase 22026-10-282026-10-26−2 days
2026-11-13Sevabertinib, metforminNCT07753252Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyPhase 12026-10-062026-10-08+2 days
2026-11-11pemetrexed, CemiplimabNCT07720167Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerPhase 22029-11-012035-08-01+2099 days
2026-11-11MethotrexateNCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisPhase 2/32026-072031-11+1949 days
2026-11-11LuxdegalutamideNCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Phase 22032-03-152026-12-03−1929 days
2026-11-11Vemurafenib, Pertuzumab, Dabrafenib, Pemigatinib, Entrectinib, Cobimetinib, Abemaciclib, Regorafenib, Tepotinib, Alectinib, Trametinib, AtezolizumabNCT05159245The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsPhase 22026-11-252031-11-25+1826 days
2026-11-11BevacizumabNCT07005570Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK)Phase 22027-07-012031-12-31+1644 days
2026-11-11aldesleukinNCT04643574NeoTIL in Advanced Solid TumorsPhase 12027-112023-10-24−1469 days
2026-11-11Obinutuzumab, GemcitabineNCT06806033Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLPhase 22027-01-312029-07-31+912 days
2026-11-11MepolizumabNCT05923047Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.Phase 42024-09-012027-01-01+852 days
2026-11-11elasomeranNCT04894435Mix and Match of the COVID-19 Vaccine for Safety and ImmunogenicityPhase 22024-11-152022-07-25−844 days
2026-11-11Rituximab, PirtobrutinibNCT06263491Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsPhase 22026-11-012028-11-01+731 days
2026-11-11BrigatinibNCT03707938Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerPhase 12026-01-282028-01-28+730 days
2026-11-11PelacarsenNCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Phase 32028-08-242026-10-15−679 days
2026-11-11RilvegostomigNCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCPhase 1/22026-08-282028-06-01+643 days
2026-11-11lutikizumab, risankizumabNCT06865105Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPhase 22027-122029-08+609 days
2026-11-11SintilimabNCT06054906Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric CancerPhase 22025-06-302026-12-30+548 days
2026-11-11Colchicine (cardiovascular)NCT06217120Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection FractionPhase 22025-10-012027-04+547 days
2026-11-11InclisiranNCT06865885LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringPhase 42026-12-302028-06-01+519 days
2026-11-11Capecitabine, GemcitabineNCT06434493Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar CholangiocarcinomaPhase na2028-06-012029-11-01+518 days
2026-11-11DexamethasoneNCT07330999Three Variants of the PENG Block With and Without Perineural Adjuvants in Older AdultsPhase na2027-08-312026-05-20−468 days
2026-11-11Nab-paclitaxel, GemcitabineNCT03492671Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerPhase 22026-092027-10+395 days
2026-11-11metforminNCT07001878Cannabis Potency Effects on Brain White Matter in Early Phase PsychosisPhase 42026-08-312027-09-30+395 days
2026-11-11MepolizumabNCT06041386REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyPhase 42025-01-312026-02-12+377 days
2026-11-11Trastuzumab Deruxtecan, OlaparibNCT06525298EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsPhase 1/22027-092028-09+366 days
2026-11-11CemiplimabNCT05574101A Study of Radiation Therapy and Cemiplimab for People With Skin CancerPhase 22026-10-062027-10-06+365 days
2026-11-11Fianlimab, CemiplimabNCT06848088A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentPhase 22029-10-102030-10-09+364 days
2026-11-11BofanglutideNCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossPhase 32027-092026-09-22−344 days
2026-11-11EsketamineNCT05450432Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionPhase 42026-06-012027-05-01+334 days
2026-11-11TislelizumabNCT07557914Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesPhase 22029-022029-12+303 days
2026-11-11VebreltinibNCT07549061Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLCPhase 22028-05-302027-09-01−272 days
2026-11-11Fianlimab, Cemiplimab, PembrolizumabNCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPhase 32026-07-272027-01-15+172 days
2026-11-11BevacizumabNCT06106308Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationPhase 22026-112027-04-16+166 days
2026-11-11GemcitabineNCT06454383Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic CancerPhase 12026-11-132027-03-23+130 days
2026-11-11BelumosudilNCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsPhase 12026-09-282027-01-26+120 days
2026-11-11Rosuvastatin, elecoglipronNCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsPhase 12026-10-012027-01-25+116 days
2026-11-11UlonivirineNCT07595263A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)Phase 12027-01-152026-09-29−108 days
2026-11-11Nab-paclitaxel, BevacizumabNCT05075993Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsPhase 12027-02-022026-11-03−91 days
2026-11-11HiCM-188 (allogeneic iPSC-cardiomyocytes)NCT07646210HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryPhase 1/22028-052028-02−90 days
2026-11-11Bofanglutide, Semaglutide (Ozempic)NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusPhase 32026-12-112026-09-18−84 days
2026-11-11Tirzepatide (Zepbound)NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialPhase 2/32027-01-012026-10-10−83 days
2026-11-11Rosuvastatin, BofanglutideNCT07128888Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionPhase 12026-07-052026-04-13−83 days
2026-11-11Rifaximin (Xifaxan)NCT05677282Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide AdjunctPhase 42025-092025-06-29−64 days
2026-11-11Ranibizumab, BevacizumabNCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)Phase 32026-072026-05-28−34 days
2026-11-11tocilizumabNCT07254637Tocilizumab in Chronic Inflammatory CPPD DiseasePhase 22026-102026-11+31 days
2026-11-11retatrutideNCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightPhase 32027-072027-06−30 days
2026-11-11linaclotideNCT06692673Linaclotide for Colonoscopy Bowel PrepPhase 1/22026-04-302026-04-07−23 days
2026-11-11AfliberceptNCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Phase 32026-102026-09-09−22 days
2026-11-11Cabotegravir/rilpivirine (Cabenuva)NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedPhase 32029-09-042029-08-13−22 days
2026-11-11remibrutinibNCT07855276A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSPhase 12027-12-212027-11-29−22 days
2026-11-11AMG 691NCT07745907A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese VolunteersPhase 12027-03-312027-03-17−14 days
2026-11-11BofanglutideNCT07141030Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionPhase 12025-10-092025-10-20+11 days
2026-11-11IbrutinibNCT03479268Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaPhase 12026-11-052026-10-28−8 days
2026-11-11BofanglutideNCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExercisePhase 32026-08-072026-07-30−8 days
2026-11-11VCT220NCT07340320A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusPhase 22027-04-162027-04-08−8 days
2026-11-11metreleptinNCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLPhase 32026-07-212026-07-14−7 days
2026-11-11zenagamtide, Semaglutide (Ozempic)NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 32028-12-122028-12-19+7 days
2026-11-11Naloxone (Narcan)NCT07459166A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadePhase 22026-07-222026-07-15−7 days
2026-11-11ModafinilNCT07830056Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived PersonnelPhase 42026-102026-09-24−7 days
2026-11-11rilzabrutinibNCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanPhase 32026-11-302026-11-25−5 days
2026-11-11BofanglutideNCT07355738Bioequivalence Study of GZR18 Injection Before and After CMC ChangePhase 12026-05-202026-05-22+2 days
2026-11-11lebrikizumabNCT01987492A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent AsthmaPhase 22016-12-202016-12-19−1 day
2026-11-10PembrolizumabNCT05394103Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsPhase 1/22025-12-302029-03-31+1187 days
2026-11-10IncobotulinumtoxinA (Xeomin)NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Phase 32011-092013-11-12+803 days
2026-11-10NivolumabNCT05964101Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaPhase 22025-08-012027-08-01+730 days
2026-11-10Ocrevus Zunovo, OcrelizumabNCT07667322A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisPhase 12028-02-152026-09-01−532 days
2026-11-10AmbroxolNCT06193421High-Dose Ambroxol in GBA1-Related ParkinsonPhase 1/22025-02-272026-03-30+396 days
2026-11-10QuemliclustatNCT05688215Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaPhase 1/22026-12-012027-12-31+395 days
2026-11-10Tremelimumab, DurvalumabNCT05701488SIRT With Tremelimumab and Durvalumab for Resectable HCCPhase 12026-10-012027-10-01+365 days
2026-11-10Cladribine (MAVENCLAD®), natalizumabNCT04178005Cladribine Tablets After Treatment With Natalizumab (CLADRINA)Phase 42026-08-302027-05-30+273 days
2026-11-10DexamethasoneNCT07607691Ultrasound-Guided PENG Block for Chronic Shoulder PainPhase na2026-10-012027-07-01+273 days
2026-11-10Venetoclax, Ibrutinib, Lenalidomide, ObinutuzumabNCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaPhase 1/22026-12-012027-08-12+254 days

Showing the newest 300 of 2,453 moves. Each drug page lists every registry date for its own studies.

Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.